INVESTABOT
Equity Research
XNAS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-08-27. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-07-02. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-07-02. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-05-06. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-26. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-18. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-05. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-01. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-05-29. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-05-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
Vertex Pharmaceuticals (VRTX) had 2 Form 144 pre-sale notices filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 0 unique sellers · 6 accumulating - 7 trimming - 1 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 8, 2026 | van Grunsven Jasper | EVP, CP and NPPO | GRANT | 8,682 | — | — |
| August 28, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | GRANT | 5,000 | — | — |
| August 27, 2026 | Sachs Bruce I | — | GIFT | -6,000 | — | — |
| July 21, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | GRANT | 8,251 | — | — |
| July 21, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | GRANT | 8,251 | — | — |
| July 15, 2026 | Sachs Bruce I | — | GRANT | 99.94 | $475 | ~$47K |
| July 15, 2026 | Garber Alan M | — | GRANT | 31.56 | $475 | ~$15K |
| July 2, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | SELL | -1,500 | $525 | ~$0.8M |
| July 2, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | SELL | -1,541 | $519 | ~$0.8M |
| July 1, 2026 | Liu Joy | EVP and Chief Legal Officer | SELL | -828 | $503 | ~$0.4M |
| June 26, 2026 | Bozic Carmen | EVP and CMO | SELL | -596 | $483 | ~$0.3M |
| June 18, 2026 | Bozic Carmen | EVP and CMO | SELL | -1,020 | $462 | ~$0.5M |
| June 15, 2026 | Bozic Carmen | EVP and CMO | SELL | -4,062 | $450 | ~$1.8M |
| June 5, 2026 | Bozic Carmen | EVP and CMO | SELL | -1,745 | $450 | ~$0.8M |
| June 1, 2026 | Liu Joy | EVP and Chief Legal Officer | SELL | -828 | $440 | ~$0.4M |
| May 29, 2026 | Bozic Carmen | EVP and CMO | SELL | -1,974 | $450 | ~$0.9M |
| May 15, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | SELL | -33 | $453 | ~$15K |
| May 15, 2026 | Bozic Carmen | EVP and CMO | SELL | -1,354 | $453 | ~$0.6M |
| May 12, 2026 | Bozic Carmen | EVP and CMO | SELL | -6,988 | $450 | ~$3.1M |
| May 4, 2026 | Bhatia Sangeeta N. | — | SELL | -318 | $424 | ~$0.1M |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| August 27, 2026 | Bruce I. Sachs | — | — | SEC |
| July 2, 2026 | McKechnie Duncan | — | 1,541 | SEC |
| July 2, 2026 | Tatsis Ourania | — | 1,500 | SEC |
| July 1, 2026 | Liu Joy | — | 828 | SEC |
| June 26, 2026 | Bozic Carmen | — | 596 | SEC |
| June 18, 2026 | Bozic Carmen | — | 1,020 | SEC |
| June 15, 2026 | Bozic Carmen | — | 4,062 | SEC |
| June 5, 2026 | Bozic Carmen | — | 1,745 | SEC |
| June 1, 2026 | Liu Joy | — | 828 | SEC |
| May 29, 2026 | Bozic Carmen | — | 1,974 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| September 10, 2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 24,109,373 | ~$12.0B | 0.6% | August 7, 2026 |
| Vanguard Group | 24,105,823 | ~$10.9B | — | January 29, 2026 |
| BlackRock | 23,751,989 | ~$10.8B | — | February 12, 2026 |
| BlackRock | 23,969,517 | ~$10.7B | 0.9% | May 13, 2026 |
| BlackRock | 21,312,244 | ~$10.0B | — | August 13, 2024 |
| State Street | 11,871,459 | ~$5.9B | 1.2% | August 7, 2026 |
| State Street | 11,689,539 | ~$5.3B | — | February 13, 2026 |
| State Street | 11,730,139 | ~$5.2B | 0.3% | May 15, 2026 |
| JP Morgan Chase | 6,674,600 | ~$3.3B | -7.5% | August 12, 2026 |
| JP Morgan Chase | 7,219,956 | ~$3.2B | 17.6% | May 13, 2026 |
| JP Morgan Chase | 6,141,281 | ~$2.8B | — | February 11, 2026 |
| Morgan Stanley | 3,242,139 | ~$1.6B | 1.7% | August 13, 2026 |
| Morgan Stanley | 3,188,881 | ~$1.4B | 2.2% | May 15, 2026 |
| Morgan Stanley | 3,120,310 | ~$1.4B | — | May 27, 2026 |
| Goldman Sachs | 2,531,961 | ~$1.3B | 2.6% | August 14, 2026 |
| Goldman Sachs | 2,466,575 | ~$1.1B | 36.1% | May 15, 2026 |
| Fidelity (FMR) | 2,212,596 | ~$1.0B | — | February 17, 2026 |
| Fidelity (FMR) | 2,020,265 | ~$902.1M | -8.7% | May 15, 2026 |
| Goldman Sachs | 1,812,218 | ~$821.6M | — | March 25, 2026 |
| Fidelity (FMR) | 1,457,158 | ~$723.8M | -27.9% | August 13, 2026 |